Oxysterol Signatures Distinguish Age-Related Macular Degeneration from Physiologic Aging
- PMID: 29903570
- PMCID: PMC6021272
- DOI: 10.1016/j.ebiom.2018.05.035
Oxysterol Signatures Distinguish Age-Related Macular Degeneration from Physiologic Aging
Abstract
Macrophage aging is pathogenic in numerous diseases, including age-related macular degeneration (AMD), a leading cause of blindness in older adults. Although prior studies have explored the functional consequences of macrophage aging, less is known about its cellular basis or what defines the transition from physiologic aging to disease. Here, we show that despite their frequent self-renewal, macrophages from old mice exhibited numerous signs of aging, such as impaired oxidative respiration. Transcriptomic profiling of aged murine macrophages revealed dysregulation of diverse cellular pathways, especially in cholesterol homeostasis, that manifested in altered oxysterol signatures. Although the levels of numerous oxysterols in human peripheral blood mononuclear cells and plasma exhibited age-associated changes, plasma 24-hydroxycholesterol levels were specifically associated with AMD. These novel findings demonstrate that oxysterol levels can discriminate disease from physiologic aging. Furthermore, modulation of cholesterol homeostasis may be a novel strategy for treating age-associated diseases in which macrophage aging is pathogenic.
Keywords: Age-related macular degeneration; Aging; Cholesterol; Lipids.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.
Figures
Comment in
-
Cholesterol homeostasis, macrophage malfunction and age-related macular degeneration.Ann Transl Med. 2018 Nov;6(Suppl 1):S55. doi: 10.21037/atm.2018.10.31. Ann Transl Med. 2018. PMID: 30613630 Free PMC article. No abstract available.
References
-
- van Leeuwen R., Klaver C.C., Vingerling J.R., Hofman A., de Jong P.T. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol. 2003;18(9):845–854. - PubMed
-
- Ferris F.L., 3rd, Fine S.L., Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640–1642. Chicago, Ill: 1960. - PubMed
-
- Kim J.H., Lee D.W., Chang Y.S., Kim J.W., Kim C.G. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Fortschr Ophthalmol. 2016;254(11):2101–2109. - PubMed
-
- Inoue M., Yamane S., Sato S., Sakamaki K., Arakawa A., Kadonosono K. Comparison of time to retreatment and visual function between Ranibizumab and Aflibercept in age-related macular degeneration. Am J Ophthalmol. 2016;169:95–103. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
